Literature DB >> 15377655

The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO.

Jörn Lausen1, Seongeun Cho, Shaohua Liu, Milton H Werner.   

Abstract

The acute human leukemias are associated with the presence of chimeric gene products that arise from spontaneous chromosomal translocations. The t(8;21) translocation gene product led to the discovery of the Eight Twenty-One (ETO) gene. When fused to RUNX1, ETO is thought to mediate the formation of a repressive complex at RUNX1-dependent genes. ETO has also been found to act as a co-repressor of the promyelocytic zinc finger and Bcl-6 oncoproteins, suggesting that it may play a common role as a transcriptional co-repressor leading to human disease. An analysis of ETO-mediated repression revealed that one of the key binding partners of ETO is the nuclear receptor co-repressor (N-CoR). It is shown that two highly conserved domains of ETO interact with repression domains I and III of N-CoR. One of the ETO domains displays significant homology to Drosophila TAF(II)110, whereas the other is a predicted zinc binding motif that engages a conserved PPLXP motif in repression domain III of N-CoR. Together, these domains of ETO cooperate in repression with N-CoR and the binding sites in N-CoR overlap with those for other repressive factors. Thus, ETO has the potential to participate in a number of repressive complexes, which can be distinguished by their binding partners and target genes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377655     DOI: 10.1074/jbc.M407239200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.

Authors:  Daniela Salat; Robert Liefke; Jörg Wiedenmann; Tilman Borggrefe; Franz Oswald
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

2.  Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.

Authors:  Sangho Park; Wei Chen; Tomasz Cierpicki; Marco Tonelli; Xiongwei Cai; Nancy A Speck; John H Bushweller
Journal:  Blood       Date:  2009-02-09       Impact factor: 22.113

3.  Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

Authors:  Yizhou Liu; Wei Chen; Justin Gaudet; Matthew D Cheney; Liya Roudaia; Tomasz Cierpicki; Rachel C Klet; Kari Hartman; Thomas M Laue; Nancy A Speck; John H Bushweller
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

4.  Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.

Authors:  Linping Chen-Wichmann; Marina Shvartsman; Caro Preiss; Colin Hockings; Roland Windisch; Enric Redondo Monte; Georg Leubolt; Karsten Spiekermann; Jörn Lausen; Christian Brendel; Manuel Grez; Philipp A Greif; Christian Wichmann
Journal:  Oncogene       Date:  2018-08-09       Impact factor: 9.867

5.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Authors:  Liya Roudaia; Matthew D Cheney; Ekaterina Manuylova; Wei Chen; Michelle Morrow; Sangho Park; Chung-Tsai Lee; Prabhjot Kaur; Owen Williams; John H Bushweller; Nancy A Speck
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation.

Authors:  Olga N Kuvardina; Julia Herglotz; Stephan Kolodziej; Nicole Kohrs; Stefanie Herkt; Bartosch Wojcik; Thomas Oellerich; Jasmin Corso; Kira Behrens; Ashok Kumar; Helge Hussong; Henning Urlaub; Joachim Koch; Hubert Serve; Halvard Bonig; Carol Stocking; Michael A Rieger; Jörn Lausen
Journal:  Blood       Date:  2015-04-24       Impact factor: 22.113

7.  Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Authors:  Eun-Young Ahn; Ming Yan; Oxana A Malakhova; Miao-Chia Lo; Anita Boyapati; Hans Beier Ommen; Robert Hines; Peter Hokland; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

8.  Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance depends on integral membrane anchoring of FKBP38.

Authors:  Sandra Barth; Frank Edlich; Utta Berchner-Pfannschmidt; Silke Gneuss; Günther Jahreis; Philippe A Hasgall; Joachim Fandrey; Roland H Wenger; Gieri Camenisch
Journal:  J Biol Chem       Date:  2009-06-22       Impact factor: 5.157

9.  PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1.

Authors:  Lucas Schneider; Stefanie Herkt; Lei Wang; Christine Feld; Josephine Wesely; Olga N Kuvardina; Annekarin Meyer; Thomas Oellerich; Björn Häupl; Erhard Seifried; Halvard Bonig; Joern Lausen
Journal:  Oncogenesis       Date:  2021-05-17       Impact factor: 7.485

10.  Structural and functional analysis of the DEAF-1 and BS69 MYND domains.

Authors:  Fatiha Kateb; Helene Perrin; Konstantinos Tripsianes; Peijian Zou; Roberta Spadaccini; Matthew Bottomley; Titus M Franzmann; Johannes Buchner; Stephane Ansieau; Michael Sattler
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.